| 前收盘价格 | 35.68 |
| 收盘价格 | 35.78 |
| 成交量 | 439,670 |
| 平均成交量 (3个月) | 571,368 |
| 市值 | 1,742,199,168 |
| 价格/销量 (P/S) | 3.21 |
| 股市价格/股市净资产 (P/B) | 3.22 |
| 52周波幅 | |
| 利润日期 | 13 Feb 2025 - 17 Feb 2025 |
| 营业毛利率 | -8.70% |
| 营业利益率 (TTM) | -6.39% |
| 稀释每股收益 (EPS TTM) | -0.830 |
| 季度收入增长率 (YOY) | 17.90% |
| 总债务/股东权益 (D/E MRQ) | 16.59% |
| 流动比率 (MRQ) | 3.62 |
| 营业现金流 (OCF TTM) | 10.40 M |
| 杠杆自由现金流 (LFCF TTM) | 11.41 M |
| 资产报酬率 (ROA TTM) | -3.51% |
| 股东权益报酬率 (ROE TTM) | -8.39% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Instruments & Supplies (US) | 混合的 | 混合的 |
| Medical Instruments & Supplies (全球的) | 混合的 | 混合的 | |
| 股票 | AtriCure, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
-0.4
| 分析师共识 | 4.0 |
| 内部交易活动 | -3.0 |
| 价格波动 | -1.5 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.40 |
|
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States. |
|
| 部门 | Healthcare |
| 行业 | Medical Instruments & Supplies |
| 投资方式 | Small Core |
| 内部持股比例 | 3.18% |
| 机构持股比例 | 105.56% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 61.00 (Canaccord Genuity, 70.70%) | 购买 |
| 中 | 40.00 (11.94%) | |
| 低 | 36.00 (Oppenheimer, 0.74%) | 购买 |
| 平均值 | 43.40 (21.45%) | |
| 总计 | 5 购买 | |
| 平均价格@调整类型 | 33.99 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| JP Morgan | 17 Dec 2024 | 40.00 (11.94%) | 购买 | 31.50 |
| 30 Oct 2024 | 40.00 (11.94%) | 购买 | 34.83 | |
| Canaccord Genuity | 09 Dec 2024 | 61.00 (70.70%) | 购买 | 33.94 |
| 30 Oct 2024 | 53.00 (48.31%) | 购买 | 34.83 | |
| Needham | 30 Oct 2024 | 40.00 (11.94%) | 购买 | 34.83 |
| Oppenheimer | 30 Oct 2024 | 36.00 (0.74%) | 购买 | 34.83 |
| UBS | 30 Oct 2024 | 40.00 (11.94%) | 购买 | 34.83 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| NOZNESKY JUSTIN J | - | 33.31 | -585 | -19,486 |
| 累积净数量 | -585 | |||
| 累积净值 ($) | -19,486 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 33.31 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| NOZNESKY JUSTIN J | 职员 | 11 Dec 2024 | 处理 (-) | 585 | 33.31 | 19,486 |
| 日期 | 类型 | 细节 |
|---|---|---|
| 20 Nov 2024 | 公告 | AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference |
| 07 Nov 2024 | 公告 | AtriCure to Participate in the Stifel 2024 Healthcare Conference |
| 29 Oct 2024 | 公告 | AtriCure Reports Third Quarter 2024 Financial Results |
| 28 Oct 2024 | 公告 | AtriCure to Participate in the UBS Global Healthcare Conference |
| 15 Oct 2024 | 公告 | AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management |
| 08 Oct 2024 | 公告 | AtriCure to Announce Third Quarter 2024 Financial Results |
| 01 Oct 2024 | 公告 | AtriCure Receives CE-Mark for the EnCompass® Clamp |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合